Search

Your search keyword '"Nakashima, Ichiro"' showing total 86 results

Search Constraints

Start Over You searched for: Author "Nakashima, Ichiro" Remove constraint Author: "Nakashima, Ichiro" Publisher elsevier bv Remove constraint Publisher: elsevier bv
86 results on '"Nakashima, Ichiro"'

Search Results

5. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Outcomes from the phase 3 CHAMPION-NMOSD trial

8. Associations between neuromyelitis optica spectrum disorder, Sjögren's syndrome, and conditions with electrolyte disturbances

9. Application of diagnostic criteria for optic neuritis – Authors' reply

11. Myelin oligodendrocyte glycoprotein antibody-associated disease in a patient with symptoms of aseptic meningitis who achieved spontaneous remission: A case report and review of the literature

12. Diagnosis and classification of optic neuritis

13. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD

15. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration

19. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease

20. A 23-year follow-up report of juvenile-onset Sandhoff disease presenting with a motor neuron disease phenotype and a novel variant

21. Long-term efficacy and safety of eculizumab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder

23. Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence

24. A nation-wide survey of Japanese pediatric MOG antibody-associated diseases

25. Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension

30. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

32. Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody

37. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients

39. Steroid-responsive recurrent tumefactive demyelination with multiple petechial hemorrhages along non-displaced medullary veins

40. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

46. Clinical time course of pediatric acute disseminated encephalomyelitis

47. Rituximab was effective for acute disseminated encephalomyelitis followed by recurrent optic neuritis with anti-myelin oligodendrocyte glycoprotein antibodies

Catalog

Books, media, physical & digital resources